Status: Currently Official on 13-Feb-2025
Official Date: Official as of 01-Dec-2014
Document Type: USP Monographs
DocId: GUID-863BFA83-E393-4FAA-84E8-E0D0A5CF21ED_1_en-US
DOI: https://doi.org/10.31003/USPNF_M8229_01_01
DOI Ref: 74eti

© 2025 USPC Do not distribute

Benazepril Hydrochloride Compounded Oral Suspension, Veterinary

DEFINITION

Benazepril Hydrochloride Compounded Oral Suspension, Veterinary contains NLT 90.0% and NMT 110.0% of the labeled amount of benazepril hydrochloride ($C_{24}H_{28}N_2O_5 \cdot HCI$).

Prepare Benazepril Hydrochloride Compounded Oral Suspension, Veterinary, 5 mg/mL, as follows (see Pensions (795)).

Benazepril Hydrochloride powder	500 mg
Vehicle: a 1:1 mixture of Ora-Plus ^a and Ora-Sweet ^a , a sufficient quantity to make	100 mL

^a Perrigo Pharmaceuticals, Allegan, MI.

Pour the *Benazepril Hydrochloride powder* into a suitable container. Wet the powder with a small amount of *Vehicle*, and triturate to make a smooth paste. Add the *Vehicle* to make the contents pourable. Transfer the contents, stepwise and quantitatively, to a calibrated container using the remainder of the *Vehicle*. Add sufficient *Vehicle* to bring to final volume. Shake to mix well.

ASSAY

• Procedure

Solution A: 25 mM sodium phosphate adjusted with phosphoric acid to a pH of 3.0. Pass through a nylon filter of 0.45-µm pore size.

Mobile phase: Acetonitrile and Solution A (40:60)

Diluent: Water adjusted with phosphoric acid to a pH of 3.0

Standard stock solution: 5 mg/mL of <u>USP Benazepril Hydrochloride RS</u> in *Diluent*. Sonicate for 3 min. Mix well, and store at 2°-8°.

Standard solution: 0.01 mg/mL of benazepril hydrochloride prepared with *Standard stock solution* and *Diluent*. Centrifuge for 5 min at 14,000 rpm, and use the supernatant. Protect from light, and store at 2°–8°.

Sample solution: Shake thoroughly each bottle of Oral Suspension, Veterinary. Transfer 2.0 mL of the Oral Suspension, Veterinary into a 1-L volumetric flask, and dilute with *Diluent* to volume. Mix well. Centrifuge for 5 min at 14,000 rpm, and use the supernatant. Protect from light, and store at 2°-8°.

Chromatographic system

(See Chromatography (621), System Suitability.)

Mode: LC

Detector: UV 210 nm

Column: 4.6-mm × 25-cm; 5-µm packing L1

Temperatures
Column: 30°
Autosampler: 5°
Flow rate: 1.2 mL/min
Injection volume: 25 µL

System suitability

Sample: Standard solution

[Note—The retention time for benazepril hydrochloride is about 6.5 min.]

Suitability requirements Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0% for replicate injections

Analysis

Samples: Standard solution and Sample solution

 $Calculate \ the \ percentage \ of \ the \ labeled \ amount \ of \ benazepril \ hydrochloride \ (C_{24}H_{28}N_2O_5 \cdot HCI) \ in \ the \ portion \ of \ Oral \ Suspension,$

Veterinary taken:

https://trungtamthuoc.com/

= peak response of benazepril hydrochloride from the Sample solution

r_s = peak response of benazepril hydrochloride from the *Standard solution*

 C_s = concentration of benazepril hydrochloride in the Standard solution (mg/mL)

 C_{II} = nominal concentration of benazepril hydrochloride in the Sample solution (mg/mL)

Acceptance criteria: 90.0%-110.0%

SPECIFIC TESTS

• <u>PH (791)</u>: 3.8-4.8

ADDITIONAL REQUIREMENTS

- PACKAGING AND STORAGE: Package in tight, light-resistant containers. Store at 2°-8° or at controlled room temperature.
- LABELING: Label it to indicate that it is to be well-shaken before use, and to state the *Beyond-Use Date*. Label it to state that it is for veterinary use only.
- BEYOND-USE DATE: NMT 90 days after the date on which it was compounded when stored at 2°-8° or at controlled room temperature
- USP REFERENCE STANDARDS (11)

USP Benazepril Hydrochloride RS

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
BENAZEPRIL HYDROCHLORIDE COMPOUNDED ORAL SUSPENSION, VETERINARY	Brian Serumaga Science Program Manager	CMP2020 Compounding 2020

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 39(5)

Current DocID: GUID-863BFA83-E393-4FAA-84E8-E0D0A5CF21ED_1_en-US

DOI: https://doi.org/10.31003/USPNF_M8229_01_01

DOI ref: 74eti